Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Subscribe To Our Newsletter & Stay Updated